- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07622251
The Effect of Exercise on Cognitive Functions in Individuals With Systemic Lupus Erythematosus
30. mai 2026 oppdatert av: Nejla Uzun, Istanbul Galata University
Sistemik Lupus Eritematozus Tanılı Bireylere Uygulanan Aerobik Egzersizlerin Kognitif Fonksiyonlar ve Hastalık Aktivitesi Üzerine Etkisi
Study Objective:
To examine the effect of aerobic exercise on disease activity and cognitive functions in patients diagnosed with SLE. Study Goals:
- To conduct comprehensive pre- and post-treatment (after 12 weeks) evaluations of SLE patients included in the study, and to determine their disease activity and cognitive levels.
- To apply aerobic exercise to SLE patients for three months.
- To analyze the effects of the aerobic exercise program on disease activity and cognitive functions.
Studieoversikt
Status
Har ikke rekruttert ennå
Intervensjon / Behandling
Detaljert beskrivelse
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by exacerbation and remission phases, affecting many organs, tissues, and systems, including the musculoskeletal system, as a result of increased autoantibody production and immune complex formation.
The disease can manifest with a wide range of clinical features, including symptoms such as fatigue, fever, weight loss or weight gain, as well as arthritis or arthralgia, mucocutaneous lesions with a characteristic butterfly rash, alopecia, oral ulcers, cardiac involvement, vasculitis, Raynaud's phenomenon, nephritis, gastrointestinal symptoms, neuropsychiatric symptoms, and hematological abnormalities.
In addition to these symptoms, cognitive dysfunction is common in SLE at all ages.
Studies in the literature have highlighted the impact on many cognitive functions in SLE.
Attention, memory, and verbal fluency have been identified as the most affected functions.
In inflammatory rheumatic diseases, regular physical activity, consisting of aerobic exercises and strengthening programs, is known to have a long-term anti-inflammatory effect.
Exercise, in particular, has been shown to be a safe method for improving many symptoms in SLE, including health-related quality of life, depressive symptoms, or, more importantly, fatigue.
The 2018 EULAR recommendations suggest that for individuals with inflammatory arthritis and osteoarthritis, aerobic training intensity should be at least 30 minutes, 5 days a week (150 minutes per week with intervals as needed), at moderate intensity (starting at 40-50% of VO2 max and gradually progressing to 50-85% of target VO2 max if the patient has high fatigue), including the use of large muscle groups, and performed without exacerbating the patient's existing fatigue complaints.
Virtual reality-based rehabilitation, on the other hand, involves interaction through smell, sound, and touch in a computer-generated environment using three-dimensional computer simulations to create realistic events and objects.
Another aspect of exercise that has attracted attention in recent years is its effectiveness on cognitive functions.
Exercise is increasingly recognized as a promising non-pharmacological method for preserving, improving, and even preventing the decline of human cognitive functions.
Research examining the effectiveness of exercise on cognitive functions has focused on specific age groups and populations.
These studies primarily focus on diseases such as Parkinson's, Alzheimer's, Dementia, and Mild Cognitive Impairment.
Looking at studies examining the effectiveness of exercise on cognitive functions in rheumatological diseases, improvement on the Montreal Cognitive Assessment Scale was found in patients with Rheumatoid Arthritis who underwent only one of the following exercises for three months: walking, cycling, or swimming.
According to our research, studies examining the effectiveness of aerobic exercise on cognitive functions in rheumatoid diseases are quite limited.
No studies investigating the combined effectiveness of aerobic exercise on cognitive functions, whether applied alone or in combination, were found in patients with SLE.
The aim of this study is to examine the effect of aerobic exercise on disease activity and cognitive functions in patients diagnosed with SLE.
Studietype
Intervensjonell
Registrering (Antatt)
38
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: nejla uzun
- Telefonnummer: +905076426043
- E-post: fizyoterapist_nejla@hotmail.com
Studiesteder
-
-
-
Istanbul, Tyrkia (Türkiye)
- Istanbul Galata University
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- Having been diagnosed with SLE at least one year prior according to the American Rheumatology Association (ACR) diagnostic criteria
- Being between 25-65 years of age
- Not having received a neuropsychiatric diagnosis
- Having medication adjusted and being on stable medication for 3 months
- Not being involved in a regular exercise program
- Having a Mini Mental Test score lower than 26.
Exclusion Criteria:
- History of secondary rheumatic disease
- Presence of active acute or chronic infection,
- Body mass index (BMI) ≥ 30 kg/m2,
- Acute renal failure,
- Cardiac and pulmonary involvement,
- Presence of musculoskeletal and joint disorders that prevent exercise testing,
- Pregnancy
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Ingen inngripen: Kontrollgruppe
|
|
|
Eksperimentell: treningsgruppe
|
Aerobic Exercise + video based games +calisthenics exercise
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Mini Mental Test
Tidsramme: baseline and 12th week
|
baseline and 12th week
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Stroop Test
Tidsramme: baseline and 12th week
|
baseline and 12th week
|
|
Corsi Block Test
Tidsramme: baseline and 12th week
|
baseline and 12th week
|
|
Wisconsin Card Sorting Test
Tidsramme: baseline and 12th week
|
baseline and 12th week
|
|
Six-Minute Walk Test
Tidsramme: baseline and 12th week
|
baseline and 12th week
|
|
borg scale
Tidsramme: every sessions
|
every sessions
|
|
Systemic Lupus Erythematosus Disease Activity Index
Tidsramme: baseline and 12th week
|
baseline and 12th week
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
5. juni 2026
Primær fullføring (Antatt)
4. juni 2027
Studiet fullført (Antatt)
10. august 2027
Datoer for studieregistrering
Først innsendt
10. mai 2026
Først innsendt som oppfylte QC-kriteriene
30. mai 2026
Først lagt ut (Faktiske)
3. juni 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
3. juni 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
30. mai 2026
Sist bekreftet
1. mai 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- E-77300296-050.04-16331
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .